A health economic simulation model for the clinical management of osteoporosis

Abstract

Summary

The objective was to estimate the burden of osteoporosis in Sweden based on current clinical practice and the cost-effectiveness of improvements in the management of osteoporosis over the clinical management compared to current clinical practice. Results showed that better compliance to treatment guidelines is associated with better projected outcomes and cost-savings.

Introduction

The purpose of this study is to estimate the burden of osteoporosis in Sweden based on current clinical practice and the cost-effectiveness of improvements in the management of osteoporosis over the clinical management compared to current clinical practice.

Methods

The analysis was carried out using a model that simulates the individual patients considered for pharmacological treatment during 1 year and their projected osteoporosis treatment pathway, quality-adjusted life years (QALYs) and costs over their remaining lifetime. All patients regardless of treatment or no treatment were simulated. Information on current management of osteoporosis in terms of patient characteristics and treatment patterns were derived from a Swedish osteoporosis research database based on national registers and patient records. Current (standard) clinical management was compared with alternative scenarios mirroring Swedish treatment guidelines.

Results

The national burden in terms of lost QALYs was estimated at 14,993 QALYs and the total economic cost at €776M. Scenario analyses showed that 382–3864 QALYs could be gained at a cost/QALY ranging from cost-saving to €31368, depending on the scenario. The margin of investment, i.e. the maximum amount that could be invested in the healthcare system to achieve these improvements up to the limit of the willingness to pay/QALY, was estimated at €199M on a population level (€3,634/patient).

Conclusions

The analysis showed that better compliance to treatment guidelines is associated with better projected outcomes and cost-savings. From a cost-effectiveness perspective, there is also considerable room for investment to achieve these improvements in the management of osteoporosis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Johnell, O. and J.A. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos International, 2006(0937-941X (Print))

  2. 2.

    Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1-2):136. https://doi.org/10.1007/s11657-013-0136-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Strom O et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6(1-2):59–155. https://doi.org/10.1007/s11657-011-0060-1

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Fleurence RL, Iglesias CP, Johnson JM (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. PharmacoEconomics 25(11):913–933. https://doi.org/10.2165/00019053-200725110-00003

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982. https://doi.org/10.1007/s00198-010-1424-x

    Article  PubMed  Google Scholar 

  6. 6.

    Jonsson E, Eriksson D, Åkesson K, Ljunggren Ö, Salomonsson S, Borgström F, Ström O (2015) Swedish osteoporosis care. Arch Osteoporos 10:222. https://doi.org/10.1007/s11657-015-0222-7

    Article  PubMed  Google Scholar 

  7. 7.

    Solomon DH et al (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Landfeldt E, Ström O, Robbins S, Borgström F (2012) Adherence to treatment of primary osteoporosis and its association to fractures–the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433–443. https://doi.org/10.1007/s00198-011-1549-6

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Strom O et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries–an economic evaluation based on the fracture intervention trial. Osteoporos Int 18(8):1047–1061. https://doi.org/10.1007/s00198-007-0349-5

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781–1793. https://doi.org/10.1007/s00198-006-0193-z

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669–674. https://doi.org/10.1007/s001980070064

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427. https://doi.org/10.1007/s001980170112

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Statistics Sweden Ettårig livslängdstabell, dödsrisker (promille) efter kön, ålder och år [One year life expectancy, mortality (per mille) by sex, age and year]. 2015, Statistics Sweden: http://www.statistikdatabasen.scb.se/sq/20061

  14. 14.

    Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24(4):1491–1502. https://doi.org/10.1007/s00198-012-2115-6

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112. https://doi.org/10.1007/s00198-003-1516-y

    Article  PubMed  Google Scholar 

  16. 16.

    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513–521. https://doi.org/10.1001/jama.2009.50

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473. https://doi.org/10.1016/S8756-3282(03)00061-9

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    von Friesendorff M, McGuigan FE, Wizert A, Rogmark C, Holmberg AH, Woolf AD, Akesson K (2016) Hip fracture, mortality risk, and cause of death over two decades. Osteoporos Int 27(10):2945–2953. https://doi.org/10.1007/s00198-016-3616-5

    Article  Google Scholar 

  19. 19.

    Tandvårds- och Läkemedelsförmånsverket (The Dental and Pharmaceutical Benefits Agency), Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar in TLVAR 2017:1, T.-o. Läkemedelsförmånsverket, Editor. 2017

  20. 20.

    Borgstrom F et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17(5):637–650. https://doi.org/10.1007/s00198-005-0015-8

    Article  PubMed  Google Scholar 

  21. 21.

    The Dental and Pharmaceutical Benefits Agency (TLV), Läkemedelsdatabas. 2016, The Dental and Pharmaceutical Benefits Agency

  22. 22.

    Södra Regionvårdsnämnden, Regionala priser och ersättningar för södra sjukvårdsregionen 2016. 2015

  23. 23.

    Statistics Sweden, Consumer price index (1980=100) [online database]. 2016: http://www.scb.se/hitta-statistik/statistik-efter-amne/priser-och-konsumtion/konsumentprisindex/konsumentprisindex-kpi/

  24. 24.

    The Riksbank, Search interest & exchange rate [online database], Riksbanken (Sweden's central bank), editor. 2016: http://www.riksbank.se/en/Interest-and-exchange-rates/search-interest-rates-exchange-rates/

  25. 25.

    Zethraeus, N., et al., Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. N. SSE/EFI Working Paper Series in Economics and Finance, Editor. 2002

  26. 26.

    Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621–635. https://doi.org/10.1023/A:1013171831202

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    National Institute for Health and Care Excellence (NICE), Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. 2008

  28. 28.

    Läkemedelsverket (Medical Products Agency), Behandling av osteoporos för att förebygga frakturer–Behandlingsrekommendation. 2004

  29. 29.

    Svensson M, Nilsson FO, Arnberg K (2015) Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. PharmacoEconomics 33(11):1229–1236. https://doi.org/10.1007/s40273-015-0307-6

    Article  PubMed  Google Scholar 

  30. 30.

    Socialstyrelsen (National Board of Health and Welfare), Nationella riktlinjer för sjukdomsförebyggande metoder 2011 Hälsoekonomiskt underlag [National guidelines for disease prevention methods 2011]. 2011

  31. 31.

    Socialstyrelsen (National Board of Health and Welfare), Nationella riktlinjer för rörelseorganens sjukdomar 2012. 2012

  32. 32.

    Marsh D et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22(7):2051–2065. https://doi.org/10.1007/s00198-011-1642-x

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Sale JE et al (2011) Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int 22(7):2067–2082. https://doi.org/10.1007/s00198-011-1544-y

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22(7):2083–2098. https://doi.org/10.1007/s00198-011-1534-0

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Cooper C, Atkinson EJ, O’Fallon WM, Melton LJ 3rd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7(2):221–227. https://doi.org/10.1002/jbmr.5650070214

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Javaid MK et al (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture(R) Best Practice Framework tool. Osteoporos Int 26(11):2573–2578. https://doi.org/10.1007/s00198-015-3192-0

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the guidance of the Epidemiology and Quality of Life Working Group of the Committee of Scientific Advisors of the International Osteoporosis Foundation. The study was financed with an unrestricted grant from Medtronic.

Author information

Affiliations

Authors

Corresponding author

Correspondence to E. Jonsson.

Ethics declarations

Conflicts of interest

EJ, AH and FB have previously consulted for companies marketing products for osteoporosis. ÖJ, AS, KÅ, JK declare that they have no conflict of interest.

Ethics approval

This research was approved by Stockholm ethics vetting committee decision 2013/1543-31/4.

Electronic supplementary material

Fig. 5
figure5

Simulated current clinical management from index-event. Each point in the graph, from right to left, shows the proportion of patients by each start-cohort (index-event). From the index-event, patients to the decision tree and undergo BMD measurement or not move to treatment decision, and the projected treatment status at years 1, 5 and 10 after index-event. The width of the lines indicates the proportion of patients within each state. (GIF 369 kb)

High-resolution image (TIFF 330 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jonsson, E., Hansson-Hedblom, A., Ljunggren, Ö. et al. A health economic simulation model for the clinical management of osteoporosis. Osteoporos Int 29, 545–555 (2018). https://doi.org/10.1007/s00198-017-4325-4

Download citation

Keywords

  • Cost
  • Fracture
  • Osteoporosis
  • Quality-of-life
  • Register
  • Sweden